Wall Street analysts’ outlook for Personalis Inc (PSNL)

Personalis Inc (NASDAQ: PSNL) stock jumped 22.73% on Monday to $1.35 against a previous-day closing price of $1.10. With 3.07 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.35 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $1.5600 whereas the lowest price it dropped to was $1.1450. The 52-week range on PSNL shows that it touched its highest point at $4.31 and its lowest point at $0.89 during that stretch. It currently has a 1-year price target of $4.70. Beta for the stock currently stands at 1.64.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PSNL was up-trending over the past week, with a rise of 26.17%, but this was up by 42.47% over a month. Three-month performance dropped to -23.73% while six-month performance fell -35.71%. The stock lost -46.00% in the past year, while it has lost -31.82% so far this year. A look at the trailing 12-month EPS for PSNL yields -2.38 with Next year EPS estimates of -1.75. For the next quarter, that number is -0.50. This implies an EPS growth rate of 10.73% for this year and 20.87% for next year. EPS is expected to decline by -13.70% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -26.59%.

Float and Shares Shorts:

At present, 46.71 million PSNL shares are outstanding with a float of 39.30 million shares on hand for trading. On Oct 30, 2023, short shares totaled 0.74 million, which was 1.52% higher than short shares on Sep 28, 2023. In addition to Mr. Christopher M. Hall as the firm’s President, CEO & Director, Mr. Aaron L. Tachibana serves as its CFO & COO.

Institutional Ownership:

Through their ownership of 76.02% of PSNL’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 31.75% of PSNL, in contrast to 27.64% held by mutual funds. Shares owned by individuals account for 18.70%. As the largest shareholder in PSNL with 11.79% of the stake, ARK Investment Management LLC holds 5,719,427 shares worth 5,719,427. A second-largest stockholder of PSNL, JPMorgan Investment Management, I, holds 2,288,976 shares, controlling over 4.72% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in PSNL, holding 2,053,485 shares or 4.23% stake. With a 12.46% stake in PSNL, the ARK Genomic Revolution ETF is the largest stakeholder. A total of 6,046,006 shares are owned by the mutual fund manager. The JPMorgan Small Cap Growth Fund, which owns about 3.18% of PSNL stock, is the second-largest Mutual Fund holder. It holds 1,541,901 shares valued at 1.48 million. Vanguard Total Stock Market ETF holds 2.84% of the stake in PSNL, owning 1,375,373 shares worth 1.32 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PSNL since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With PSNL analysts setting a high price target of $7.50 and a low target of $2.30, the average target price over the next 12 months is $4.70. Based on these targets, PSNL could surge 455.56% to reach the target high and rise by 70.37% to reach the target low. Reaching the average price target will result in a growth of 248.15% from current levels.

Summary of Insider Activity:

Insiders traded PSNL stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 1 while that of sell transactions has risen to 20 over the past year. The total number of shares bought during that period was 10,000 while 56,885 shares were sold.